Executive order to elevate US pharma manufacturing signed by Trump
.png)
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
The order aims to restore robust domestic manufacturing in the US, with directions for the US FDA to streamline regulatory reviews and provide early support for domestic manufacturers. The order also includes other directives such as allowing the Environmental Protection Agency to accelerate the construction of facilities for prescription drug, API, and raw materials manufacturing, and ensuring federal agencies issue permits for domestic pharmaceutical manufacturing facilities. The US FDA will also be directed to improve the reporting of active ingredients sourced from foreign producers, with considerations to “publicly display a list of facilities that do not comply”.
FDA Commissioner Marty Makary stated that with the signing of the executive order, the federal agency will plan to conduct surprise inspections of overseas plants in order to bring the oversight of such facilities in line with US policies and interests. On estimates from analysts that bringing a new manufacturing facility to the US could take at least 5 years, the White House stated that such a timeline was “unacceptable from a national security standpoint”. Trump stated, “As we invest in the future, we will permanently bring our medical supply chains back home. We will produce our medical supplies, pharmaceuticals, and treatments right here in the United States”.
As the threat of tariffs on imported pharmaceuticals has yet to clarify what such procedures will look like, Trump commented at the signing of the order that an announcement could be made in the next 2 weeks. Currently, the US imports over US$200 billion worth of prescription drugs and related materials.
Sources:
1. Trump signs executive order to encourage US drug manufacturing [Accessed May 7, 2025] https://www.reuters.com/business/healthcare-pharmaceuticals/trump-sign-order-encourage-domestic-drug-manufacturing-wapo-reports-2025-05-05/
2. Fact Sheet: President Donald J. Trump Announces Actions to Reduce Regulatory Barriers to Domestic Pharmaceutical Manufacturing [Accessed May 7, 2025] https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-reduce-regulatory-barriers-to-domestic-pharmaceutical-manufacturing/
Related News
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
-
News Women in Pharma: Building from the ground up together
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance